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Abstract
Background Multiple tumor foci of intrahepatic cholangiocarcinoma (ICC) are often considered a contra-indication for resection.
We sought to define long-term outcomes after resection of ICC in patients with multiple foci.
Methods Patients who underwent resection for ICC between 1990 and 2017 were identified from 12 major HPB centers.
Outcomes of patients with solitary lesions, multiple lesions (ML), and oligometastases (OM) were compared. OM were defined
as extrahepatic metastases spread to a single organ.
Results One thousand thirteen patients underwent resection of ICC. On final pathology, 185 patients (18.4%) had ML and 27
(2.7%) had OM. Median survival of patients with a solitary tumor was 43.2 months, while the median survival of patients with 2
tumors was 21.2 months; the median survival of patients with 3 or more tumors was 15.3 months (p < 0.001). Five-year survival
was 43.3%, 28.0%, and 8.6%, respectively. The median survival of patients without OM was 37.8 months versus 14.9 months
among patients with OM (p < 0.001); estimated 5-year survival was 39.3% and 10.6%, respectively. In multivariable analysis, the
presence of two lesions was not an independent poor prognostic factor for OS (HR 1.19; 95%CI 0.90–1.57; p = 0.229). However,
the presence of three or more tumors was an independent poor prognostic factor for OS (HR 1.97; 95%CI 1.48–2.64; p < 0.001).
Conclusion Resection of multiple liver tumors for patients with ICC did not preclude 5-year survival: in particular, estimated 5-
year OS for resection of two tumors was 28.0%.
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Introduction
Intrahepatic cholangiocarcinoma (ICC) is the second most
common primary malignancy of the liver with an incidence
of 1–2 per 100,000 persons.1, 2 ICC occurs in the bile duct of
the peripheral liver parenchyma and often presents late due to
the absence of ear ly symptoms.3 About 10% of
cholangiocarcinomas are ICC.4, 5ICC is associatedwith chronic
liver disease secondary to cirrhosis and chronic hepatitis C
infection in Western countries.6 ICC is also associated with
hepatolithiasis, liver fluke infestation, and bile duct
malformations such as choledochal cysts.7–11 Nevertheless,
the underlying liver disease is often not identified and the ma-
jority of ICC cases are incidental.
The American Joint Committee on Cancer (AJCC) staging
manual is the most commonly used staging model for ICC.12
According to the AJCCmanual, patients with multiple lesions
(ML) or extrahepatic oligometastases (OM) are considered to
have less favorable stages and these features often are consid-
ered a contra-indication for resection. In fact, the European
Association for the Study of the Liver (EASL) in their 2014
guidelines state that ML and OM should be considered rela-
tively strong contraindications to surgery.13
Complete resection is the only available curative treatment
for ICC, even though it is attainable only in 15–25% of
patients.14–17 Resection is not without risk, with high periop-
erative morbidity and mortality associated with (extended)
hemihepatectomies.18–20 Unresectable ICC is associated with
a median survival of only 5 months, which can be prolonged
with chemotherapy to 12 months in which 70% of patients
experience grade 3 or 4 toxicity.21–23 Given the debate regard-
ing how to manage patients with multiple ICC lesions, the
current study sought to define long-term outcome after resec-
tion of ICC among patients with ML or OM.
Methods
Patients undergoing resection for ICC between January 1,
1990, and December 31, 2017, were identified from one of
12 participating major hepatobiliary institutions in the USA,
Asia, Australia, and Europe (Johns Hopkins University,
Baltimore, MD; Emory University, Atlanta, GA; Stanford
University Medical Center, Stanford, CA; University of
Virginia Health System, Charlottesville, VA; Fundeni
Clinical Institute, Bucharest, Romania; Beaujon Hospital,
Clichy, France; Curry Cabral Hospital, Lisbon, Portugal;
Eastern Hepatobiliary Surgery Hospital, Shanghai, China;
Ottowa General Hospital, Ottowa, Canada; Royal Prince
Alfred Hospital, Sydney, Australia; San Raffaele Hospital,
Milan, Italy; Erasmus MC, University Medical Centre
Rotterdam, Rotterdam, the Netherlands). Patients who did
not undergo resection, patients who had a macroscopically
positive resection margin and patients who received a liver
transplantation, were excluded. Only patients with histologi-
cally confirmed cholangiocarcinoma were included.
Institutional review boards of every participating institution
approved this study.
Demographic and clinical data were retrieved from hospital
records and included age, sex, BMI, and presence of jaundice.
Patient operative risk was estimated using the American
Society of Anesthesiologists physical status classification
system.24 Pathological data such as tumor number, tumor size,
major vascular invasion, presence of extrahepatic disease,
presence of nodal metastases, final resection margin, and the
presence of vascular and/or perineural invasion were also re-
trieved. Data on treatment-related variables, such as the type
of surgery and lymphadenectomy were recorded. A minor
hepatectomy was defined as a hepatic resection of less than
three Couinaud segments. Margin status was categorized as
R0 for tumor negative resection margins and R1 for micro-
scopically positive margins. ML were categorized in two le-
sions and three or more lesions. In some previous studies, ML
have been divided into intrahepatic metastases, lesions at a
larger distance from the index tumor or in another segment,
and satellite lesions, lesions approximating the index tumor/in
the same segment. Because no definitive definition of
intrahepatic metastases and satellite lesions exists, we opted
to consider both as Bmultiple lesions^.25 OM were defined as
metastases limited to a single extrahepatic organ.
Data on short- and long-term outcomes were collected.
Short-term outcomes included length of hospital stay (LOS),
postoperative morbidity, and mortality. The date of last
follow-up and vital status was also collected for all patients.
Survival was calculated from the date of index operation.
Long-term outcomes were stratified based on multiple lesions
and oligometastases.
Statistical Analysis
Summary statistics were provided as whole numbers and per-
centages for categorical variables and medians with interquar-
tile range (IQR) for continuous variables. The distribution of
categorical variables was tested using the χ2 test or Fisher’s
exact test, as appropriate. The distribution of continuous var-
iables was tested using the Mann–Whitney U test. The prima-
ry outcome of interest was overall survival (OS), defined as
the time interval between the date of surgery and the date of
death or last follow-up, as appropriate. Estimates for OS were
calculated using the Kaplan-Meier method. Differences in OS
were assessed using the Log-Rank test. A multivariable Cox
proportional hazards model was used to identify potential risk
factors. In the multivariable regression, previously described
risk factors, including R1 resection, lymph node metastases,
invasion of adjacent organs, and tumor size, were included.
Patients with OM were excluded from the multivariable
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analysis, as metastases that are not resected have such a seri-
ous effect on long-term outcomes that these patients were not
readily comparable with the other included patients. Results
from the Cox proportional hazards model were reported as
hazard ratios (HR) and their corresponding 95% confidence
intervals (CI). Multiple imputation was used to correct for
missing data in the multivariable analysis. All analyses were
performed using SPSS 24.0 (IBM,NewYork) and the rms and
mice packages for R 3.5.1 (https://cran.r-project.org/). All




In total, 1013 patients were included in this study (Table 1).
The median age at resection was 59 years (IQR 50–67), 540
(54.5%) patients were male, and median BMI was 25.4 (22.6–
28.2). Preoperative jaundice was present in a minority of pa-
tients (n = 90, 8.9%). Most patients were classified as ASA II
(n = 489; 52.0%) or III (n = 280; 29.8%) and were treated in
the last decade (n = 862; 85.1%) with a major surgical proce-
dure (n = 593; 58.9%). Distribution across centers for all pa-
tients was reported in Supplemental Table 1. ML were more
frequently treated in the west and in Australia. OM were
resected only in Europe and the USA. Median follow-up after
resection was 29.3 months and 507 patients (50.4%) died
during follow-up.
The average tumor size was 6.2 cm (IQR: 4.3–9.0). Major
vascular invasion was noted in 100 (10.0%) patients; micro-
vascular and perineural invasion was present in 254 (25.7%)
and 149 (16.3%) patients, respectively. Direct invasion into
adjacent organs was present in 77 (7.7) patients. Multiple tu-
mors were present in 185 patients (18.4%). Patients with ML
had a median of two tumors (interquartile range [IQR] 2–3,
range 2–11). Oligometastases outside of the liver were present
in 27 patients at the time of resection, most of which were
located in the peritoneum (n = 11; 1.1%) and distant lymph
nodes (n = 9; 0.9%). These oligometastases were resected in
20/27 patients.
Number of Tumors
Perioperative outcomes and pathological characteristics were
stratified by presence of ML in Table 2. In general, patients
with ML had more perioperative complications and more ad-
vanced disease at pathological examination. Patients with
multiple tumors were more likely to have lymph node metas-
tases (25.4% vs. 15.5%; p = 0.001) and were more likely to
have disease extension beyond the liver (15.8% vs. 5.9%;
p < 0.001). ML more often necessitated a major resection
(72.4% vs. 55.9%; p < 0.001). Postoperative complications
were higher in patients with multiple tumors (49.7% vs.
41.8%; p = 0.049). Length of stay did not differ across groups.
Recurrence occurred in 430 (52.4%) patients with a solitary
tumor versus 137 (74.1%) patients with ML (p < 0.001).
Patients with OM, like patients with ML, were diagnosed
with worse prognostic factors and had worse perioperative
outcomes (Table 3). In particular, patients with OMwere more
likely to have R1 margins (34.6% vs. 12.2%; p = 0.003),
lymph node metastases (55.6% vs. 16.3%; p < 0.001), and
invasion outside of the liver (48.1% vs. 6.6%; p < 0.001).
Complications occurred more frequently in patients with
Table 1 Baseline characteristics





Age, years 59 (50–67)
BMI 25.4 (22.6–28.2)











Preoperative chemotherapy 55 (5.4)
Major resection 593 (58.9)
Size, cm 6.2 (4.3–9.0)
Major vascular invasion 100 (10.0)
Microvascular invasion 254 (25.7)
Perineural invasion 149 (16.3)
Extension into adjacent organs 77 (7.7)
R1 resection 128 (12.8)
Lymph node metastases 175 (17.3)
Multiple lesions
Median number of tumors 2 (2–3)
2 lesions 107 (10.7)




Distant lymph nodes 9 (0.9)
Other 5 (0.5)
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OM (70.4% vs. 42.7%; p = 0.004). Postoperative mortality
was also much higher than in patients without oligometastases
(22.2% vs. 5.6%, respectively; p = 0.004). There was no sig-
nificant difference in recurrence (63.0% vs. 56.0%; p =
0.472).
Survival Estimates
Overall survival was compared among patients with and with-
out multiple lesions (Fig. 1). Median OS of patients with two
tumors was 21.2 months and median OS of patients with three
or more tumors was 15.3 months, while patients with only a
single tumor had a median OS of 43.2 months (p < 0.001). At
5 years follow-up, 28.0% of patients with two tumors were
still alive vs. 43.3% of patients with a single tumor. A simi-
larly large difference was observed in median OS between
patients with and without OM (14.9 months vs. 37.8 months;
p < 0.001; Fig. 2). Five-year survival for patients with OM
was 10.6% versus 39.3 for patients without OM.
In multivariable analysis (Table 4), known risk factors for
early mortality in patients with ICC were included. Factors
significantly associated with survival included R1 resection
margin (HR 1.48; 95%CI 1.12–1.95; p = 0.005), lymph node
metastases (HR 1.88; 95%CI 1.48–2.39; p < 0.001), invasion
Table 2 Postoperative outcomes
stratified by intrahepatic
metastases
Variable Single tumor (n = 821) Multiple tumors (n = 185) p value*
Preoperative chemotherapy 40 (4.9) 15 (8.1) 0.080
R1 margin 97 (11.9) 29 (15.8) 0.154
Lymph node metastases 127 (15.5) 47 (25.4) 0.001
Oligometastases 20 (2.4) 7 (3.8) 0.314
Direct invasion other organ 48 (5.9) 29 (15.8) < 0.001
Perineural invasion 118 (15.9) 30 (18.0) 0.505
Major vascular invasion 76 (9.3) 23 (12.5) 0.189
Major resection 458 (55.9) 131 (72.4) < 0.001
Postoperative complication 343 (41.8) 92 (49.7) 0.049
Clavien–Dindo grade 0.036
I-II 207 (60.0) 44 (47.8)
IIIa-V 138 (40.0) 48 (52.2)
90-day postoperative mortality 50 (6.1) 11 (5.9) 0.941
Length of stay, days 12 (7–17) 12 (7–18) 0.668
Recurrence 430 (52.4) 137 (74.1) < 0.001
*Fisher’s exact test was used for categorical variables with expected counts < 5
Table 3 Postoperative outcomes
stratified by the presence of
oligometastases
Variable No oligometastases (n = 982) Oligometastases (n = 27) p value*
Preoperative chemotherapy 52 (5.3) 3 (11.1) 0.178
R1 margin 119 (12.2) 9 (34.6) 0.003
Lymph node metastases 160 (16.3) 15 (55.6) < 0.001
Multiple lesions 178 (18.2) 7 (25.9) 0.314
Direct invasion other organ 64 (6.6) 13 (48.1) < 0.001
Perineural invasion 143 (16.2) 5 (19.2) 0.596
Major vascular invasion 95 (9.7) 5 (18.5) 0.179
Major resection 571 (58.4) 20 (74.1) 0.104
Postoperative complication 419 (42.7) 19 (70.4) 0.004
Clavien–Dindo Grade 0.691
I-II 241 (57.2) 10 (52.6)
IIIa-V 180 (42.8) 9 (47.4)
90-day postoperative mortality 55 (5.6) 6 (22.2) 0.004
Length of stay, days 12 (7–17) 13 (9–20) 0.197
Recurrence 550 (56.0) 17 (63.0) 0.472
*Fisher’s exact test was used for categorical variables with expected counts < 5
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into adjacent organs (HR 1.63; 95%CI 1.17–2.29; p = 0.004),
and size in centimeter (HR 1.05; 95%CI 1.02–1.07;
p < 0.001). The presence of two lesions was not an indepen-
dent poor prognostic factor for OS (HR 1.19; 95%CI 0.90–
1.57; p = 0.229). However, the presence of three or more tu-
mors was an independent poor prognostic factor for OS (HR
1.97; 95%CI 1.48–2.64; p < 0.001).
Discussion
In this study of more than 1000 patients who underwent cura-
tive resection for ICC, the number of tumors had a large
impact on the median OS. Specifically, OS was 43.2 months
for solitary tumors, 21.2 months for two tumors, and
15.3 months for three or more tumors (p < 0.001). However,
resection of multiple tumors did not preclude 5-year survival
as the estimated 5-year OS for resection of two tumors was
28.0%. Previously, multiple tumor foci have been considered
a relative contra-indication for resection in guidelines.12, 13, 26
In comparison, median OS for systemic chemotherapy and
locoregional ablative treatments (e.g., radio-embolization)
rarely exceeds 12 months.23, 27–32In the current study, on mul-
tivariable analysis, the presence of more than two lesions was
an independent poor prognostic factor, while the presence of
two lesions was not.
Overall survival, months
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107 73 39 28 23 11 2 Lesions




Numbers at Risk 815
Fig. 1 Overall survival stratified
by presence of intrahepatic
metastases (p < 0.001)
Overall survival, months
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Fig. 2 Overall survival stratified
by presence of oligometastases
(p < 0.001)
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Although a comprehensive definition of intrahepatic me-
tastases does not exist, intrahepatic metastases of ICC are
most commonly defined as tumor processes at larger dis-
tances, e.g., 2 cm from the index tumor, or in another
Couinaud segment of the liver.33, 34 It is currently insufficient-
ly understood, whether satellite lesions, tumors within the
same segment and close to the index tumor, have a separate
natural history from intrahepatic metastases.25 Theoretically,
tumors at larger distance would have a larger impact on prog-
nosis because these lesions may represent hematogenous
intrahepatic dissemination.25, 35 The use of Couinaud seg-
ments, a model for macroscopic liver anatomy, seems arbi-
trary, as it has no basis in physiology or carcinogenesis.36
Two recent smaller-scale studies demonstrate the possibility
for long-term survival for both intrahepatic metastases and
satellite lesions.37, 38 However, only in one of these could a
rather small difference in survival between satellites and dis-
tant liver metastases be demonstrated.37 Because of these rea-
sons, we opted to consider lesions of both categories as
Bmultiple lesions.^
Many small studies have attempted to evaluate clinical out-
comes after ML and a systematic review has confirmed the
gravity of this prognostic factor.39–41 Mostly, studies confirm
that there is a correlation between ML and prognostic factors
of advanced disease, such as lymph node metastases, vascular
involvement, and distant metastases. Because of the relative
rarity of ICC, however, whether ML are an absolute contra-
indication for surgery, especially in absence of other aggravat-
ing factors, remains unclear. In this large multi-institutional
study, enough statistical power was available to account for
confounding factors in multivariable analysis. As such, we
were able to confirm the prognostic importance of ML, with
a median difference in survival of 21 months for two tumors
and 15 months for three or more tumors in univariable analy-
sis. In addition, patients withMLwere shown to have a higher
likelihood of lymph node metastases, direct invasion into
adjacent organs, and necessity of a major resection. Of note,
after correcting for possible confounding factors,MLwere not
a significant prognostic factor in multivariable analysis, and
the estimated difference in survival in a cohort without other
risk factors was minimal.
Local techniques for management of ICC include hepatic
arterial infusion, TACE, and chemo-embolization. These tech-
niques have in common that they rely on the dual blood sup-
ply of the liver.42–44 Hepatic arterial infusion therapy works by
continuous infusion of floxuridine directly into the hepatic
artery. A study based on two prospective trials suggests 5-
year survival can be as high as 20%.45 In similar studies,
TACE has been observed to have a 3-year survival of
15%.42, 46 Radio-embolization has an observed 3-year surviv-
al of 15%.42 The results of this study indicate that in well-
selected patients with ML, superior results can be achieved
with complete resection. Because of the minimally invasive
nature of local techniques, the comorbidity after application is
lower than for resection. Even using the latest techniques,
oncologic liver resection has a reported comorbidity of 30–
50% and a mortality of up to 3–5%.18, 47 In this study, the
postoperative complications and mortality were more com-
mon in patients with ML. Better long-term survival combined
with higher postoperative complications necessitated a strict
selection of patients with ML for surgical resection.
Like ML, a definitive definition for oligometastases does
not exist and the literature on this subject is scarce. In this
study, we defined OM as spread to one extrahepatic organ.
Even with this definition, only 27 patients were identified, 20
of whom also underwent resection of these metastases. Long-
term outcome after survival was poor, with only an estimated
10% of patients surviving to 5 years after resection. Like
intrahepatic metastases, OM correlated with other predictors
of poor survival, such as lymph node metastases, a positive
resection margin and direct growth into neighboring organs.
Postoperative outcomes after resection were significantly
worse in patients with OM. These poor perioperative out-
comes, combined with a grave prognosis indicate that restraint
should be exercised when deciding to resect OM. More, ide-
ally, prospective data is necessary for evaluating the advan-
tages and drawbacks of surgery for this patient population.
This study has several strengths and weaknesses. To our
knowledge, this is the largest available study assessing the
long-term outcomes of surgery for ML and OM. This made
it possible to perform multivariable analyses, leading to more
precise estimates of survival correlation. Because no follow-
up protocol was in place, we have opted to limit ourselves to
the more objective OS as an outcome. The multicentricity of
this study made the data presented herein more broad appli-
cability worldwide. Even so, due to the small number of pa-
tients with oligometastases, we were not able to fully deter-
mine the subgroup of patients that would benefit from a sur-
gical resection. Apart from oncologic characteristics,
Table 4 Multivariable survival analysis
Variable Hazard ratio 95% CI p value
Age, years 1.00 1.00–1.01 0.417
ASA III/IV 1.05 0.86–1.28 0.636
R1 margin 1.48 1.12–1.95 0.005
Lymph node metastases 1.88 1.48–2.39 < 0.001
Direct expansion other organ 1.63 1.17–2.29 0.004
Perineural invasion 1.18 0.89–1.56 0.256
Major vascular invasion 1.04 0.76–1.43 0.793
Size, cm 1.05 1.02–1.07 < 0.001
Lesion number
Single lesion Ref – –
2 lesions 1.19 0.90–1.57 0.229
> 2 lesions 1.97 1.48–2.64 < 0.001
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treatment choices such as preoperative chemotherapy and oth-
er liver-directed therapies could have large impact on survival.
In this retrospective review, we cannot possibly reconstruct all
treatment choices, making a large-scale prospective study es-
pecially suited for a more detailed analysis of the preoperative
course. The result of this is the main weakness of this study:
selection bias. Included patients who underwent resection for
multiple intrahepatic tumors were part of a highly selected
cohort. Although difficulty in patient selection remains, this
study offers a credible case for not treating ML as an absolute
contra-indication. Finally, in our database, we had insufficient
data to accurately differentiate between intrahepatic metasta-
ses and satellite lesions.
Conclusion
Complete resection of multiple tumors should be considered
in selected ICC patients, especially in the presence of two
tumors.
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